

GLAXOSMITHKLINE PLC
Form 6-K/A
July 26, 2017

FORM 6-K / A

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 26 July 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

The following amendment has been made to the Director/PDMR Shareholding announcement released on 27 April 2017 in respect of the volume of notional Ordinary Shares acquired by Mr Urs Rohner (Independent Non-Executive Director) under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

Price(s) and volume(s)	Price(s)	Volume(s)
	£15.83	454.043

All other details remain unchanged.

The full amended text is shown below.

GlaxoSmithKline plc (the 'Company')

Transaction notification

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K/A

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Philip Hampton
 - b) Position/status Non-Executive Chairman
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 - b) Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.83	2,763.740
n/a (single transaction)	
 - d) Aggregated information

Aggregated volume Price
 - e) Date of the transaction 2017-04-26
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Professor Sir Roy Anderson
 - b) Position/status Independent Non-Executive Director
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882						
b)	Nature of the transaction	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.						
c)	Price(s) and volume(s)	<table border="0"> <tr> <td style="padding-right: 20px;">Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£15.83</td> <td>454.043</td> </tr> <tr> <td colspan="2">n/a (single transaction)</td> </tr> </table>	Price(s)	Volume(s)	£15.83	454.043	n/a (single transaction)	
Price(s)	Volume(s)							
£15.83	454.043							
n/a (single transaction)								

d) Aggregated information
Aggregated volume Price

e)	Date of the transaction	2017-04-26
f)	Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr Vindi Banga
b)	Position/status	Senior Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
----	---	--

	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s) Volume(s) £15.83 1,816.172 n/a (single transaction)

d) Aggregated information
Aggregated volume Price

e) Date of the transaction	2017-04-26
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Dr Vivienne Cox
 - b) Position/status Independent Non-Executive Director
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
b) Nature of the transaction	
c) Price(s) and	Price(s) Volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K/A

volume(s) £15.83 335.597
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-04-26

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms Lynn Elsenhans
b) Position/status Independent Non-Executive Director

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053

b) Nature of the transaction Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

c) Price(s) and volume(s) Price(s) Volume(s)
\$41.13 1,202.913
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-04-26

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Dr Jesse Goodman
 - b) Position/status Independent Non-Executive Director
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053

- b) Nature of the transaction

Dr Jesse Goodman was appointed to the Board with effect from 1 January 2016, as previously announced, and in accordance with the share allocation arrangements for Independent Non-Executive Directors, 25% of his fees were retained to be reinvested in notional ADSs at a date to be mutually agreed. The accumulated balance of the retained fees has now been reinvested as disclosed below.

Going forward, notional ADSs of the Company will be allocated on a quarterly basis.

Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2016 to 31 March 2017.
- c) Price(s) and volume(s)

Price(s)	Volume(s)
\$41.13	1,739.846

Aggregated information
d) Aggregated volume Price n/a (single transaction)
e) Date of the transaction 2017-04-26
f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms Judy Lewent
b) Position/status Independent Non-Executive Director
c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053

b) Nature of the transaction Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

c) Price(s) and volume(s)
Price(s) Volume(s)
\$41.13 449.364
n/a (single transaction)

Aggregated information
d) Aggregated volume Price

e) Date of the transaction 2017-04-26
f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K/A

- a) Name Mr Urs Rohner
 b) Position/status Independent Non-Executive Director
 c) Initial notification/ amendment Amendment
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £15.83 | 454.043 |
| n/a (single transaction) | |
- d) Aggregated information
 Aggregated volume Price
- e) Date of the transaction 2017-04-26
 f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 26, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc